{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T23:49:02Z","timestamp":1779234542411,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T00:00:00Z","timestamp":1469491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T00:00:00Z","timestamp":1469491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1038\/tpj.2016.53","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T10:04:15Z","timestamp":1469527455000},"page":"454-460","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Genetic variation in catechol-O-methyltransferase modifies effects of clonidine treatment in chronic fatigue syndrome"],"prefix":"10.1038","volume":"16","author":[{"given":"K T","family":"Hall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Kossowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T F","family":"Oberlander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T J","family":"Kaptchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J P","family":"Saul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V B","family":"Wyller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Fagermoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Sulheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Gjerstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Winger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K J","family":"Mukamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,26]]},"reference":[{"key":"BFtpj201653_CR1","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.metabol.2008.01.012","volume":"57","author":"K Annerbrink","year":"2008","unstructured":"Annerbrink K, Westberg L, Nilsson S, Rosmond R, Holm G, Eriksson E . Catechol O-methyltransferase val158-met polymorphism is associated with abdominal obesity and blood pressure in men. Metabolism 2008; 57: 708\u2013711.","journal-title":"Metabolism"},{"key":"BFtpj201653_CR2","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ajh.2011.93","volume":"24","author":"NC Htun","year":"2011","unstructured":"Htun NC, Miyaki K, Song Y, Ikeda S, Shimbo T, Muramatsu M . Association of the catechol-O-methyl transferase gene Val158Met polymorphism with blood pressure and prevalence of hypertension: interaction with dietary energy intake. Am J Hypertens 2011; 24: 1022\u20131026.","journal-title":"Am J Hypertens"},{"key":"BFtpj201653_CR3","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/nature06951","volume":"453","author":"K Kanasaki","year":"2008","unstructured":"Kanasaki K, Palmsten K, Sugimoto H, Ahmad S, Hamano Y, Xie L et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature 2008; 453: 1117\u20131121.","journal-title":"Nature"},{"key":"BFtpj201653_CR4","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1161\/ATVBAHA.114.303845","volume":"34","author":"KT Hall","year":"2014","unstructured":"Hall KT, Nelson CP, Davis RB, Buring JE, Kirsch I, Mittleman MA et al. Polymorphisms in catechol-O-methyltransferase modify treatment effects of aspirin on risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 2014; 34: 2160\u20132167.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFtpj201653_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jad.2014.07.016","volume":"168","author":"SF Lacerda-Pinheiro","year":"2014","unstructured":"Lacerda-Pinheiro SF, Pinheiro Junior RF, Pereira de Lima MA, Lima da Silva CG, Vieira dos Santos Mdo S, Teixeira Junior AG et al. Are there depression and anxiety genetic markers and mutations? A systematic review. J Affect Disord 2014; 168: 387\u2013398.","journal-title":"J Affect Disord"},{"key":"BFtpj201653_CR6","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1007\/s13277-013-1387-6","volume":"35","author":"C Tian","year":"2014","unstructured":"Tian C, Liu L, Yang X, Wu H, Ouyang Q . The Val158Met polymorphism in the COMT gene is associated with increased cancer risks in Chinese population. Tumour Biol 2014; 35: 3003\u20133008.","journal-title":"Tumour Biol"},{"key":"BFtpj201653_CR7","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.1158\/0008-5472.CAN-08-0043","volume":"68","author":"Y Ji","year":"2008","unstructured":"Ji Y, Olson J, Zhang J, Hildebrandt M, Wang L, Ingle J et al. Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. Cancer Res 2008; 68: 5997\u20136005.","journal-title":"Cancer Res"},{"key":"BFtpj201653_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1651-2227.2010.02072.x","volume":"100","author":"L Sommerfeldt","year":"2011","unstructured":"Sommerfeldt L, Portilla H, Jacobsen L, Gjerstad J, Wyller VB . Polymorphisms of adrenergic cardiovascular control genes are associated with adolescent chronic fatigue syndrome. Acta Paediatr 2011; 100: 293\u2013298.","journal-title":"Acta Paediatr"},{"key":"BFtpj201653_CR9","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.npp.1301227","volume":"32","author":"JA Apud","year":"2007","unstructured":"Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R et al. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 2007; 32: 1011\u20131020.","journal-title":"Neuropsychopharmacology"},{"key":"BFtpj201653_CR10","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2217\/pgs.10.206","volume":"12","author":"P Bitsios","year":"2011","unstructured":"Bitsios P, Roussos P . Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia. Pharmacogenomics 2011; 12: 559\u2013566.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201653_CR11","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.biopsych.2011.12.023","volume":"71","author":"SM Farrell","year":"2012","unstructured":"Farrell SM, Tunbridge EM, Braeutigam S, Harrison PJ . COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition. Biol Psychiatry 2012; 71: 538\u2013544.","journal-title":"Biol Psychiatry"},{"key":"BFtpj201653_CR12","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.biopsych.2009.07.008","volume":"66","author":"P Roussos","year":"2009","unstructured":"Roussos P, Giakoumaki SG, Bitsios P . Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c\/g polymorphism. Biol Psychiatry 2009; 66: 997\u20131004.","journal-title":"Biol Psychiatry"},{"key":"BFtpj201653_CR13","doi-asserted-by":"publisher","first-page":"e48135","DOI":"10.1371\/journal.pone.0048135","volume":"7","author":"KT Hall","year":"2012","unstructured":"Hall KT, Lembo AJ, Kirsch I, Ziogas DC, Douaiher J, Jensen KB et al. Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One 2012; 7: e48135.","journal-title":"PLoS One"},{"key":"BFtpj201653_CR14","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1002\/hbm.22496","volume":"35","author":"R Yu","year":"2014","unstructured":"Yu R, Gollub RL, Vangel M, Kaptchuk T, Smoller JW, Kong J . Placebo analgesia and reward processing: integrating genetics, personality, and intrinsic brain activity. Hum Brain Mapp 2014; 35: 4583\u20134593.","journal-title":"Hum Brain Mapp"},{"key":"BFtpj201653_CR15","unstructured":"Royal College of Paediatrics and Child Health. Evidence based guideline for the management of CFS\/ME (chronic fatigue syndrome\/myalgic encephalopathy) in children and young people. Royal College of Paediatrics and Child Health: London, 2004."},{"key":"BFtpj201653_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S1054-139X(97)00212-7","volume":"22","author":"KM Jordan","year":"1998","unstructured":"Jordan KM, Landis DA, Downey MC, Osterman SL, Thurm AE, Jason LA . Chronic fatigue syndrome in children and adolescents: a review. J Adolesc Health 1998; 22: 4\u201318.","journal-title":"J Adolesc Health"},{"key":"BFtpj201653_CR17","unstructured":"Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome; Board on the Health of Select Populations; Institute of Medicine. Beyond Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome: Redefining an Illness. The National Academies Press: Washington DC, 2015."},{"key":"BFtpj201653_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1744-9081-5-10","volume":"5","author":"VB Wyller","year":"2009","unstructured":"Wyller VB, Eriksen HR, Malterud K . Can sustained arousal explain the chronic fatigue syndrome? Behav Brain Funct 2009; 5: 10.","journal-title":"Behav Brain Funct"},{"key":"BFtpj201653_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1751-0759-7-5","volume":"7","author":"VB Wyller","year":"2013","unstructured":"Wyller VB, Helland IB . Relationship between autonomic cardiovascular control, case definition, clinical symptoms, and functional disability in adolescent chronic fatigue syndrome: an exploratory study. Biopsychosoc Med 2013; 7: 5.","journal-title":"Biopsychosoc Med"},{"key":"BFtpj201653_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/00008571-199606000-00007","volume":"6","author":"HM Lachman","year":"1996","unstructured":"Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM . Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996; 6: 243\u2013250.","journal-title":"Pharmacogenetics"},{"key":"BFtpj201653_CR21","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nn1438","volume":"8","author":"A Meyer-Lindenberg","year":"2005","unstructured":"Meyer-Lindenberg A, Kohn PD, Kolachana B, Kippenhan S, McInerney-Leo A, Nussbaum R et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci 2005; 8: 594\u2013596.","journal-title":"Nat Neurosci"},{"key":"BFtpj201653_CR22","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1086\/425589","volume":"75","author":"J Chen","year":"2004","unstructured":"Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004; 75: 807\u2013821.","journal-title":"Am J Hum Genet"},{"key":"BFtpj201653_CR23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/FPC.0b013e328350a274","volume":"22","author":"LV Ghimire","year":"2012","unstructured":"Ghimire LV, Kohli U, Li C, Sofowora GG, Muszkat M, Friedman EA et al. Catecholamine pathway gene variation is associated with norepinephrine and epinephrine concentrations at rest and after exercise. Pharmacogenet Genomics 2012; 22: 254\u2013260.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj201653_CR24","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1681\/ASN.2008080915","volume":"20","author":"A Haase-Fielitz","year":"2009","unstructured":"Haase-Fielitz A, Haase M, Bellomo R, Lambert G, Matalanis G, Story D et al. Decreased catecholamine degradation associates with shock and kidney injury after cardiac surgery. J Am Soc Nephrol 2009; 20: 1393\u20131403.","journal-title":"J Am Soc Nephrol"},{"key":"BFtpj201653_CR25","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1542\/peds.2006-2759","volume":"120","author":"VB Wyller","year":"2007","unstructured":"Wyller VB, Godang K, Morkrid L, Saul JP, Thaulow E, Walloe L . Abnormal thermoregulatory responses in adolescents with chronic fatigue syndrome: relation to clinical symptoms. Pediatrics 2007; 120: e129\u2013e137.","journal-title":"Pediatrics"},{"key":"BFtpj201653_CR26","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/01.HYP.8.7.611","volume":"8","author":"PA Sullivan","year":"1986","unstructured":"Sullivan PA, De Quattro V, Foti A, Curzon G . Effects of clonidine on central and peripheral nerve tone in primary hypertension. Hypertension 1986; 8: 611\u2013617.","journal-title":"Hypertension"},{"key":"BFtpj201653_CR27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0091-3057(98)00050-1","volume":"60","author":"T Murai","year":"1998","unstructured":"Murai T, Yoshida Y, Koide S, Takada K, Misaki T, Koshikawa N et al. Clonidine reduces dopamine and increases GABA in the nucleus accumbens: an in vivo microdialysis study. Pharmacol Biochem Behav 1998; 60: 695\u2013701.","journal-title":"Pharmacol Biochem Behav"},{"key":"BFtpj201653_CR28","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1007\/s00213-015-3904-3","volume":"232","author":"DR Montes","year":"2015","unstructured":"Montes DR, Stopper CM, Floresco SB . Noradrenergic modulation of risk\/reward decision making. Psychopharmacology 2015; 232: 2681\u20132696.","journal-title":"Psychopharmacology"},{"key":"BFtpj201653_CR29","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamapediatrics.2013.4647","volume":"168","author":"D Sulheim","year":"2014","unstructured":"Sulheim D, Fagermoen E, Winger A, Andersen AM, Godang K, Muller F et al. Disease mechanisms and clonidine treatment in adolescent chronic fatigue syndrome: a combined cross-sectional and randomized clinical trial. JAMA Pediatr 2014; 168: 351\u2013360.","journal-title":"JAMA Pediatr"},{"key":"BFtpj201653_CR30","first-page":"117","volume":"15","author":"E Fagermoen","year":"2015","unstructured":"Fagermoen E, Sulheim D, Winger A, Andersen A, Gjerstad J, Godan K et al. Effects of low-dose clonidine on cardiovascular and autonomic variables in adolescents with chronic fatigue: a randomized controlled trial. BMC 2015; 15: 117.","journal-title":"BMC"},{"key":"BFtpj201653_CR31","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/1756-0500-5-418","volume":"5","author":"E Fagermoen","year":"2012","unstructured":"Fagermoen E, Sulheim D, Winger A, Andersen AM, Vethe NT, Saul JP et al. Clonidine in the treatment of adolescent chronic fatigue syndrome: a pilot study for the NorCAPITAL trial. BMC Res Notes 2012; 5: 418.","journal-title":"BMC Res Notes"},{"key":"BFtpj201653_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jpepsy\/16.1.39","volume":"16","author":"LS Walker","year":"1991","unstructured":"Walker LS, Greene JW . The functional disability inventory: measuring a neglected dimension of child health status. J Pediatr Psychol 1991; 16: 39\u201358.","journal-title":"J Pediatr Psychol"},{"key":"BFtpj201653_CR33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0022-3999(93)90081-P","volume":"37","author":"T Chalder","year":"1993","unstructured":"Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D et al. Development of a fatigue scale. J Psychosom Res 1993; 37: 147\u2013153.","journal-title":"J Psychosom Res"},{"key":"BFtpj201653_CR34","doi-asserted-by":"publisher","first-page":"682","DOI":"10.2466\/PR0.103.7.682-690","volume":"103","author":"M Tanaka","year":"2008","unstructured":"Tanaka M, Fukuda S, Mizuno K, Imai-Matsumura K, Jodoi T, Kawatani J et al. Reliability and validity of the Japanese version of the Chalder Fatigue Scale among youth in Japan. Psychol Rep 2008; 103: 682\u2013690.","journal-title":"Psychol Rep"},{"key":"BFtpj201653_CR35","first-page":"9","volume":"6","author":"G Kecklund","year":"1992","unstructured":"Kecklund G, Akerstedt A . The psychometric properties of the Karolinska Sleep Questionnaire. J Sleep Res 1992; 6: 9.","journal-title":"J Sleep Res"},{"key":"BFtpj201653_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0304-3959(88)90016-4","volume":"32","author":"JW Varni","year":"1988","unstructured":"Varni JW, Wilcox KT, Hanson V, Brik R . Chronic musculoskeletal pain and functional status in juvenile rheumatoid arthritis: an empirical model. Pain 1988; 32: 1\u20137.","journal-title":"Pain"},{"key":"BFtpj201653_CR37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0304-3959(83)90143-4","volume":"17","author":"RL Daut","year":"1983","unstructured":"Daut RL, Cleeland CS, Flanery RC . Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983; 17: 197\u2013210.","journal-title":"Pain"},{"key":"BFtpj201653_CR38","doi-asserted-by":"publisher","first-page":"f4313","DOI":"10.1136\/bmj.f4313","volume":"347","author":"N Saquib","year":"2013","unstructured":"Saquib N, Saquib J, Ioannidis JP . Practices and impact of primary outcome adjustment in randomized controlled trials: meta-epidemiologic study. BMJ 2013; 347: f4313.","journal-title":"BMJ"},{"key":"BFtpj201653_CR39","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/aje\/kwn359","volume":"169","author":"S Rodriguez","year":"2009","unstructured":"Rodriguez S, Gaunt TR, Day IN . Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009; 169: 505\u2013514.","journal-title":"Am J Epidemiol"},{"key":"BFtpj201653_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2344\/0003-3006-62.1.31","volume":"62","author":"JA Giovannitti Jr","year":"2015","unstructured":"Giovannitti JA Jr, Thoms SM, Crawford JJ . Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog 2015; 62: 31\u201339.","journal-title":"Anesth Prog"},{"key":"BFtpj201653_CR41","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1365-2982.2009.01263.x","volume":"21","author":"M Camilleri","year":"2009","unstructured":"Camilleri M, Busciglio I, Carlson P, McKinzie S, Burton D, Baxter K et al. Pharmacogenetics of low dose clonidine in irritable bowel syndrome. Neurogastroenterol Motil 2009; 21: 399\u2013410.","journal-title":"Neurogastroenterol Motil"},{"key":"BFtpj201653_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0009-9236(03)00087-0","volume":"74","author":"J Nurnberger","year":"2003","unstructured":"Nurnberger J, Dammer S, Mitchell A, Siffert W, Wenzel RR, Gossl M et al. Effect of the C825T polymorphism of the G protein beta 3 subunit on the systolic blood pressure-lowering effect of clonidine in young, healthy male subjects. Clin Pharmacol Ther 2003; 74: 53\u201360.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201653_CR43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.molmed.2015.02.009","volume":"21","author":"KT Hall","year":"2015","unstructured":"Hall KT, Loscalzo J, Kaptchuk TJ . Genetics and the placebo effect: the placebome. Trends Mol Med 2015; 21: 285\u2013294.","journal-title":"Trends Mol Med"},{"key":"BFtpj201653_CR44","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.pharmthera.2013.07.009","volume":"140","author":"D Murray","year":"2013","unstructured":"Murray D, Stoessl AJ . Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions. Pharmacol Ther 2013; 140: 306\u2013318.","journal-title":"Pharmacol Ther"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201653.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201653","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201653.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T11:12:39Z","timestamp":1647947559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,26]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["BFtpj201653"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2016.53","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,26]]},"assertion":[{"value":"20 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}